Home

Senex Biotechnology is a drug discovery and development company focused on cancer therapeutics. Senex’s lead program targets a protein that regulates gene expression and is required by cancer cells to adapt to adversarial conditions; such adaptation leads to cancer drug resistance and metastasis. Senex is developing highly selective small-molecule inhibitors of this protein for the treatment of presently incurable types of ovarian cancer, breast cancer, prostate cancer and leukemia. We are also investigating the utility of these inhibitors for different cancers as single agents and in combination with other therapeutics. Our latest, highly potent and selective drug candidate is being developed in a proprietary nanoparticle formulation and is anticipated to enter clinical trials within a year.